The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to ...

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily. Each year, about 40% of the ...

GlaxoSmithKline is to invest £275 ... an aseptic sterile facility to manufacture existing and new biopharmaceutical drugs. A site manufacturing active ingredients site for HIV and vaccines ...

(WHTM) — A global biopharma company just ... expand its long-time Lancaster County manufacturing facility. During a press ...

This story was originally published on BioPharma Dive. To receive daily news and insights ... Once the companies are ...

(GSK), she realized the biopharmaceutical company offered the sort of workplace where she could grow and develop a long-term career. Some friends had internships at other companies where they did ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in Singapore. GSK inked an antibody-drug conjugate deal with DualityBio and ...

GSK said the proposals are designed to improve its UK manufacturing network ... GSK has also scrapped an investment to build a new biopharmaceutical facility in Ulverston. As well as Horlicks ...

Working out of 12 manufacturing sites, the company distributed 767 million vaccine doses across more than 160 countries in 2021. More than ten million people received one of GSK’s meningococcal ...

GSK and the biopharmaceutical firm Curevac have agreed ... GSK will assume full control of developing and manufacturing the candidate vaccines and will have worldwide rights to commercialise ...